The Cooper Cos. (NYSE:COO) shares hit a new 52-week high during mid-day trading on Monday . The company traded as high as $184.48 and last traded at $184.12, with a volume of 98,788 shares trading hands. The stock had previously closed at $183.86.

A number of research analysts have issued reports on the company. Zacks Investment Research downgraded The Cooper Cos. from a “buy” rating to a “hold” rating in a research note on Friday, August 5th. Robert W. Baird increased their price target on The Cooper Cos. from $185.00 to $196.00 and gave the stock an “outperform” rating in a research note on Thursday. Piper Jaffray Cos. reiterated an “overweight” rating and set a $185.00 price target on shares of The Cooper Cos. in a research note on Tuesday, July 26th. JPMorgan Chase & Co. started coverage on The Cooper Cos. in a research note on Wednesday, July 13th. They set a “buy” rating for the company. Finally, Stifel Nicolaus increased their price target on The Cooper Cos. from $180.00 to $195.00 and gave the stock a “buy” rating in a research note on Thursday, June 30th. Four investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $168.10.

The firm’s 50 day moving average is $180.03 and its 200-day moving average is $160.13. The firm has a market cap of $8.94 billion and a PE ratio of 43.6454.

The Cooper Cos. (NYSE:COO) last posted its quarterly earnings data on Thursday, June 2nd. The medical device company reported $2.05 EPS for the quarter, beating analysts’ consensus estimates of $1.91 by $0.14. The firm had revenue of $484.80 million for the quarter. During the same period in the previous year, the business posted $1.72 EPS. The business’s revenue was up 11.5% compared to the same quarter last year. Equities analysts forecast that The Cooper Cos. will post $8.42 earnings per share for the current year.

The company also recently disclosed a semiannual dividend, which was paid on Friday, August 5th. Investors of record on Friday, July 22nd were given a dividend of $0.03 per share. This represents a yield of 0.03%. The ex-dividend date was Wednesday, July 20th.

In related news, CEO Robert S. Weiss sold 151,839 shares of the company’s stock in a transaction on Monday, June 27th. The stock was sold at an average price of $163.02, for a total transaction of $24,752,793.78. Following the completion of the sale, the chief executive officer now owns 200,617 shares in the company, valued at $32,704,583.34. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Michael Kalkstein sold 1,000 shares of the company’s stock in a transaction on Friday, July 8th. The shares were sold at an average price of $178.55, for a total value of $178,550.00. Following the sale, the director now owns 14,215 shares of the company’s stock, valued at approximately $2,538,088.25. The disclosure for this sale can be found here.

A number of hedge funds have recently bought and sold shares of the stock. Principal Financial Group Inc. boosted its stake in The Cooper Cos. by 2.7% in the fourth quarter. Principal Financial Group Inc. now owns 154,051 shares of the medical device company’s stock worth $20,674,000 after buying an additional 4,043 shares during the period. Schroder Investment Management Group boosted its stake in The Cooper Cos. by 13.1% in the fourth quarter. Schroder Investment Management Group now owns 307,100 shares of the medical device company’s stock worth $41,213,000 after buying an additional 35,600 shares during the period. Andra AP fonden boosted its stake in The Cooper Cos. by 8.8% in the fourth quarter. Andra AP fonden now owns 9,900 shares of the medical device company’s stock worth $1,329,000 after buying an additional 800 shares during the period. I.G. Investment Management LTD. boosted its stake in The Cooper Cos. by 40.6% in the fourth quarter. I.G. Investment Management LTD. now owns 30,760 shares of the medical device company’s stock worth $4,128,000 after buying an additional 8,884 shares during the period. Finally, BlackRock Advisors LLC boosted its stake in The Cooper Cos. by 6.2% in the fourth quarter. BlackRock Advisors LLC now owns 577,463 shares of the medical device company’s stock worth $77,495,000 after buying an additional 33,887 shares during the period.

The Cooper Companies, Inc (Cooper) is a medical device company. The Company operates through two business units: CooperVision, Inc (CooperVision) and CooperSurgical, Inc (CooperSurgical). CooperVision develops, manufactures and markets a range of soft contact lenses for the vision correction market. CooperVision offers Biofinity monthly spherical, toric and multifocal lenses under the Avaira brand.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.